FDA Approves Promacta for Pediatric Patients with Chronic Immune Thrombocytopenia
(Healio) – The FDA announced the approval of eltrombopag for use in children aged 6 years or older with chronic immune thrombocytopenia who experienced an insufficient response to corticosteroids, immunoglobulins or splenectomy, according to a press release. Eltrombopag (Promacta, Novartis) […]
FDA Approves Promacta for Pediatric Patients with Chronic Immune Thrombocytopenia Read More »